Profile data is unavailable for this security.
About the company
Harmony Biosciences Holdings, Inc. is a pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. WAKIX was developed for the treatment of excessive daytime sleepiness (EDS) in pediatric patients, six years and older, with narcolepsy. HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist. ZYN002 is an investigational drug product in development for the potential treatment of behavioral symptoms associated with Fragile X syndrome (FXS) and 22q11.2 deletion syndrome (22q). It also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.
- Revenue in USD (TTM)868.45m
- Net income in USD158.69m
- Incorporated2017
- Employees293.00
- LocationHarmony Biosciences Holdings Inc630 W Germantown Pike, Suite 215PLYMOUTH MEETING 19462United StatesUSA
- Phone+1 (484) 539-9800
- Fax+1 (302) 655-5049
- Websitehttps://www.harmonybiosciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Precigen Inc | 6.31m | -425.87m | 1.19bn | 143.00 | -- | 28.52 | -- | 189.28 | -1.40 | -1.40 | 0.0212 | 0.1183 | 0.0495 | -- | 11.92 | 44,118.88 | -193.82 | -38.49 | -245.09 | -47.33 | 30.32 | 49.53 | -3,912.92 | -334.29 | 3.95 | -- | 0.6893 | -- | -36.95 | -46.64 | -31.63 | -- | -25.69 | -- |
| Collegium Pharmaceutical Inc | 780.57m | 62.87m | 1.27bn | 423.00 | 23.38 | 4.20 | 4.39 | 1.63 | 1.71 | 1.71 | 20.54 | 9.51 | 0.4702 | 8.30 | 3.55 | 1,845,312.00 | 3.79 | 3.89 | 5.30 | 5.96 | 59.35 | 56.32 | 8.05 | 8.34 | 1.48 | 2.65 | 0.7285 | 0.00 | 23.62 | 20.28 | -9.13 | 18.64 | -65.83 | -- |
| Harrow Inc | 250.04m | -4.99m | 1.44bn | 382.00 | -- | 30.41 | 105.05 | 5.75 | -0.1522 | -0.1522 | 6.70 | 1.27 | 0.6998 | 5.53 | 3.81 | 654,560.20 | -1.40 | -9.11 | -1.80 | -10.89 | 74.56 | 72.78 | -1.99 | -14.34 | 2.52 | 1.11 | 0.8388 | -- | 53.32 | 31.29 | 28.39 | -- | 92.29 | -- |
| EyePoint Inc | 42.34m | -205.75m | 1.52bn | 165.00 | -- | 6.37 | -- | 35.82 | -2.99 | -2.99 | 0.617 | 2.88 | 0.1532 | 1.02 | 59.51 | 256,606.10 | -74.47 | -35.88 | -86.87 | -42.05 | 94.08 | 84.82 | -485.95 | -201.78 | 7.11 | -- | 0.00 | -- | -5.97 | 16.27 | -84.86 | -- | 80.24 | -- |
| Perrigo Company PLC | 4.25bn | -1.40bn | 1.57bn | 8.10k | -- | 0.5339 | -- | 0.3686 | -10.19 | -10.36 | 30.80 | 21.33 | 0.4678 | 2.47 | 6.37 | 525,074.10 | -15.42 | -3.52 | -17.39 | -4.03 | 35.14 | 34.70 | -32.97 | -8.36 | 1.63 | 1.91 | 0.5536 | -- | -2.75 | 0.794 | -772.62 | -- | -14.60 | 5.21 |
| Harmony Biosciences Holdings Inc | 868.45m | 158.69m | 1.64bn | 293.00 | 10.42 | 1.88 | 8.89 | 1.88 | 2.71 | 2.71 | 14.87 | 15.07 | 0.7649 | 31.60 | 9.66 | 2,964,004.00 | 13.98 | 17.23 | 17.21 | 20.92 | 77.16 | 78.84 | 18.27 | 22.32 | 3.58 | -- | 0.1583 | -- | 21.51 | 40.30 | 9.07 | -- | 528.16 | -- |
| Immunocore Holdings PLC - ADR | 400.02m | -35.51m | 1.64bn | 524.00 | -- | 4.30 | -- | 4.10 | -0.7057 | -0.7057 | 7.87 | 7.52 | 0.3852 | 0.8348 | 5.84 | 763,389.30 | -3.42 | -11.69 | -4.39 | -14.93 | 98.73 | -- | -8.88 | -32.06 | 4.01 | -- | 0.5078 | -- | 28.95 | 59.62 | 30.48 | -- | 1.95 | -- |
| Innoviva Inc | 411.33m | 271.17m | 1.65bn | 159.00 | 7.20 | 1.42 | 5.30 | 4.02 | 3.10 | 3.10 | 5.18 | 15.71 | 0.2802 | 2.84 | 4.58 | 2,586,969.00 | 18.47 | 17.66 | 20.46 | 19.58 | 74.80 | -- | 65.92 | 58.96 | 13.85 | -- | 0.1802 | -- | 14.67 | 4.08 | 1,059.22 | 3.86 | 281.45 | -- |
| Sarepta Therapeutics Inc | 2.20bn | -713.41m | 1.67bn | 835.00 | -- | 1.46 | -- | 0.7578 | -7.20 | -7.20 | 21.50 | 10.87 | 0.6012 | 0.8101 | 4.40 | 2,632,619.00 | -19.51 | -12.81 | -26.01 | -15.87 | 69.33 | 80.21 | -32.45 | -30.61 | 1.48 | -21.14 | 0.4209 | -- | 15.58 | 32.41 | -403.27 | -- | 5.09 | -- |
| Veradermics Inc | 0.00 | -53.81m | 1.68bn | 19.00 | -- | -- | -- | -- | -1.53 | -1.53 | 0.00 | 0.3731 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -60.63 | -- | -- | -- |
| ANI Pharmaceuticals Inc | 883.37m | 70.21m | 1.71bn | 970.00 | 22.85 | 3.17 | 10.12 | 1.93 | 3.33 | 3.33 | 42.25 | 24.03 | 0.6484 | 2.44 | 3.51 | 910,686.60 | 5.75 | -0.2549 | 6.96 | -0.3002 | 61.36 | 59.78 | 8.87 | -0.473 | 2.19 | 6.52 | 0.533 | -- | 43.78 | 33.48 | 448.52 | -- | 17.66 | -- |
| Vericel Corp | 276.26m | 16.52m | 1.75bn | 398.00 | 130.61 | 4.91 | 61.89 | 6.32 | 0.2633 | 0.2633 | 5.26 | 7.01 | 0.6001 | 4.05 | 3.78 | 694,118.10 | 3.59 | -0.0292 | 4.02 | -0.0331 | 74.42 | 70.68 | 5.98 | -0.0467 | 4.68 | -- | 0.0056 | -- | 16.45 | 17.34 | 59.41 | 41.97 | 59.56 | -- |
| Organon & Co | 6.22bn | 187.00m | 1.80bn | 10.00k | 9.63 | 2.39 | 3.28 | 0.289 | 0.7166 | 0.7166 | 23.86 | 2.89 | 0.4787 | 2.13 | 4.62 | 621,600.00 | 1.44 | 7.45 | 1.79 | 9.65 | 53.30 | 59.42 | 3.01 | 13.85 | 1.23 | 2.62 | 0.92 | 25.68 | -2.92 | -0.9868 | -78.36 | -39.23 | 4.38 | -- |
| Aurinia Pharmaceuticals Inc | 283.06m | 287.20m | 1.88bn | 300.00 | 6.80 | 3.22 | 6.14 | 6.65 | 2.08 | 2.08 | 2.04 | 4.39 | 0.4347 | 0.7693 | 7.26 | -- | 44.11 | -2.73 | 51.71 | -3.10 | 88.46 | 90.63 | 101.47 | -8.50 | 4.76 | -- | 0.1059 | -- | 20.38 | 41.38 | 4,893.08 | -- | -49.05 | -- |
Data as of Mar 03 2026. Currency figures normalised to Harmony Biosciences Holdings Inc's reporting currency: US Dollar USD
43.76%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 5.85m | 10.15% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 4.47m | 7.76% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 3.11m | 5.40% |
| HBM Partners AG (Investment Management)as of 31 Dec 2025 | 2.15m | 3.73% |
| American Century Investment Management, Inc.as of 31 Dec 2025 | 1.84m | 3.20% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 1.70m | 2.96% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 1.66m | 2.89% |
| LSV Asset Managementas of 31 Dec 2025 | 1.66m | 2.88% |
| Arrowstreet Capital LPas of 31 Dec 2025 | 1.49m | 2.59% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.27m | 2.21% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
